Authors
Latest:
Clinical Validation and Real-World Impact of PrecivityAD2 Test for Alzheimer Diagnosis: Joel B. Braunstein, MDThe CEO at C2N Diagnostics talked about the clinical utility of the company’s PrecivityAD2 test, which uses the p-tau 217 biomarker and amyloid-β measurements, to increase diagnostic confidence and influence treatment decisions in Alzheimer disease. [WATCH TIME: 7 minutes]
Latest:
Utilizing Aspirin to Lower Stroke Rates in Cerebral Amyloid Antipathy: Sheheryar Jamali, MDThe neurologist from Mayo Clinic discussed his abstract at AAN 2021 comparing stroke rates in patients with cerebral amyloid antipathy given treatment with aspirin.
Latest:
The Promise of Cannabinoid Therapy for Agitation in Advanced Alzheimer Disease: Brent Forester, MD, MScThe chair of psychiatry at Tufts University School of Medicine talked about a recent study that suggested synthetic tetrahydrocannabinol could reduce agitation in patients with advanced Alzheimer disease. [WATCH TIME: 5 minutes]
Latest:
An Overview of Therapeutic Options for Amyotrophic Lateral SclerosisWith an anticipated life expectancy of 3 years from the time of symptom onset, an effective treatment strategy is essential in ALS—and recent therapeutic progress has built a foundation of hope for the community.
Latest:
Best Practices for Collaborative Migraine CareDr Williams discusses best practices for taking care of patients with migraine in a collaborative manner.
Latest:
Advocating and Advancing Research in NMOSD From a Patient Perspective: Sumaira AhmedThe founder and executive director of the Sumaira Foundation shared her patient journey living with NMOSD and the progress that has been made in the field over the past decade. [WATCH TIME: 4 minutes]
Latest:
Resources for Sleep DisordersDrs C. Michael Gibson, Ashgan A. Elshinawy, and Nathaniel F. Watson share resources for the treatment of sleep disorders.
Latest:
Mechanistic Action and FDA Outlook for Omaveloxolone in Friedreich Ataxia: David R. Lynch, MD, PhDThe professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed whether omaveloxolone’s therapeutic benefit is enough for it to become the first approved therapy for Friedrich ataxia. [WATCH TIME: 2 minutes]
Latest:
Recognizing Excellence in Multiple Sclerosis Research, the Dystel Prize: Bruce Bebo, PhDThe executive vice president of research at National MS Society talked about the Dystel Prize which is presented at AAN to a recognized individual who promotes further advancements in understanding and treating MS. [WATCH TIME: 3 minutes]
Latest:
Advocating for Patients With Migraine Through Research Initiatives: Serena L. Orr, MD, MScThe pediatric neurologist and headache specialist at the University of Calgary and Alberta Children’s Hospital spoke about the need for improved funding and research efforts for the migraine population. [WATCH TIME: 5 minutes]
Latest:
Lifestyle Change for Migraine Management: Practical Tips for the Neurologist and PCP, Part 2Trigger avoidance-only strategies don’t actually help migraine patients improve. These are the proactive behaviors that do.
Latest:
Current and Future Landscape of Alzheimer Disease Treatment: Emergence of Disease Modifying TherapiesAfter years of failed drug development, the thoughts of disease-modifying therapies for Alzheimer disease are starting to become real.
Latest:
Future Directions and Takeaways Regarding Anti-CD20 Therapies in MSAhmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, share perspectives on the future of MS care, the importance of vigilance in lab testing, and why patients may need reassurance about the potential for disease control with currently available therapies.
Latest:
Managing MS in MillennialsEffectively navigating the nuances of this unique patient population will ultimately help drive innovative solutions for this generation and those to come.
Latest:
Future Directions on Understanding the Link Between Wildfire Particulates and Dementia: Joan A. Casey, PhD & Holly Elser, MD, PhD, MPHA duo of experts highlighted the need for further studies on the exploration of how exposure to wildfire particulate matter impacts neurodegenerative diseases. [WATCH TIME: 2 minutes]
Latest:
Leah Croll, MD: Importance of Mental Health of Clinicians During COVID-19 PandemicThe neurology resident at NYU Langone shared her thoughts on the need for publication of clinician-based data and why maintaining a high level of mental health remains a top priority during the COVID-19 pandemic.
Latest:
Microglia’s Role in MS and Other Neurodegenerative Diseases: Daniel Reich, MD, PhDThe senior investigator at the National Institutes of Neurological Disorders and Stroke spoke about new opportunities for research into brain lesions and microglia.
Latest:
Switching MG Treatment Due to Adverse Events or Poor Disease ControlExpert neurologists share approaches to switching MG treatment due to either poor disease control or adverse events.
Latest:
Promise of Neuroprotection in Neurodegenerative Diseases Through HGF Compounds: Kevin Church, PhDThe chief scientific officer at Athira talked about the potential of hepatocyte growth factor compounds in promoting neurotrophic signaling and providing broad neuroprotection across neurodegenerative diseases. [WATCH TIME: 6 minutes]
Latest:
Gene Therapy, Innovative Drugs, Surgical Techniques, and the Evolving Landscape of Epilepsy Care: Gregory Krauss, MDThe professor of neurology at Johns Hopkins University School of Medicine talked about the need for education to optimize treatment selection and the continually changing landscape of care for patients with epilepsy. [WATCH TIME: 5 minutes]
Latest:
Expanded Research on Targeting Mechanisms of Parkinson Disease: Rodolfo Savica, MD, PhDThe consultant in the Department of Neurology at Mayo Clinic discussed the mechanisms of action researchers should key in on for patients with Parkinson disease.
Latest:
Advice for Managing Dravet Syndrome and LGSMary Anne Meskis; Tracy Dixon-Salazar, PhD; Kelly Knupp, MD; and Joseph E. Sullivan, MD, provide advice for physicians treating patients with Dravet syndrome or LGS.
Latest:
Effect of HbA1c Elevation, Glycemic Control Following Mechanical Thrombectomy: David Baker, DOThe vascular neurologist at Cleveland Clinic provided an overview of a study that assessed the extent HbA1c impacts the relationship between mechanical thrombectomy and poor outcomes. [WATCH TIME: 3 minutes]
Latest:
Human Endogenous Retroviruses and Their Role in ALS: Avindra Nath, MDThe clinical director of the National Institute of Neurological Disorders and Stroke provided context on two recent papers that highlight a reactivation of HERV-K virus in the development of amyotrophic lateral sclerosis. [WATCH TIME: 5 minutes]
Latest:
Challenges and Opportunities Bringing Lecanemab to Neurology Community ClinicsA group of experts from The Neuron Clinic shared their experience developing a novel inclusive clinical program to treat patients with early Alzheimer disease using lecanemab.
Latest:
Need for Improved Access to and Interventions for Mental Health in Multiple Sclerosis: Louise Palmer, MAThe health research assistant at the Shepherd Center discussed the importance of interventions that address mental health for patients with multiple sclerosis, including counseling and support groups. [WATCH TIME: 2 minutes]
Latest:
Differences Between Progressive and Relapsing MS: Benjamin Segal, MDThe chair of the Department of Neurology and the director of the Neuroscience Research Institute at The Ohio State University discussed the takeaways from his lecture at ACTRIMS Forum 2021.
Latest:
Takeaways, Highlights From the Institutional Perspectives in Neurology: MS: Eric Klawiter, MD, MScThe director of the Multiple Sclerosis and Neuromyelitis Optica Unit at Massachusetts General Hospital commented on presentations given at the recent event, as well as key takeaways from his own discussion on novel imaging approaches in multiple sclerosis. [WATCH TIME: 2 minutes]
Latest:
AUPN 2022 Veterans Health Administration WorkshopGlenn Graham, MD, PhD; and Sharyl Martini, MD, PhD, moderate a discussion with 4 clincial experts to advance specialized clinical care, education and research for Veterans with movement disorders, multiple sclerosis, epilepsy and seizures, and headache. [WATCH TIME: 1 hour, 52 minutes]
Latest:
Addressing Treatment Gaps in Adolescents With Myasthenia Gravis: Jonathan Strober, MDThe director of the Muscular Dystrophy Clinic at UCSF Benioff Children’s Hospital provided insight on promising data from the phase 2/3 VIBRANCE-MG study assessing investigational nipocalimab in adolesents with myasthenia gravis. [WATCH TIME: 3 minutes]
